Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
Most Cited Paper
in Hepatocellular Carcinoma Treatment and Prognosis
18 Months Post-Publication
Class of 2026
“Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/hepatocellular-carcinoma-treatment-and-prognosis/2026/
Topics
sintilimab · Hepatocellular carcinoma · adjuvant therapy · resected hepatocellular carcinoma · High-risk HCC · PD-1/PD-L1 inhibitor · Immune checkpoint inhibitor therapy · Randomized controlled trial · Phase 2 clinical trial · Hepatectomy · Recurrence-free survival · Overall survival · postoperative adjuvant immunotherapy · Tumor recurrence · Hepatocellular carcinoma
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Hepatocellular Carcinoma Treatment and Prognosis Papers, Class of 2026. https://pri.pepkio.com/top-papers/hepatocellular-carcinoma-treatment-and-prognosis/2026. Accessed 2026-07-13. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459